Dexmedetomidine enhances tolerance to bupivacaine cardiotoxicity in the isolated rat hearts: alpha 2 adrenoceptors were not involved

Table 1 Times to defined end points in the HR, RPP and ECG after bupivacaine perfusion

Times to event (seconds)	Con	Dex	Bupi	Bupi + Dex	Bupi + Dex + Yoh		p
T_arrhythmia	–	–	160.9 ± 23.5	277.8 ± 27.1	278.1 ± 31.2	Con vs. Bupi+Dex	< 0.001
						Con vs. Bupi+Dex Yoh+	< 0.001
						Dex vs. Yoh + Dex	0.100
T_asystole	–	–	360.3 ± 11.5	546.1 ± 23.8	543.16 ± 37.2	Con vs. Dex	< 0.001
						Con vs. Yoh + Dex	< 0.001
						Dex vs. Yoh + Dex	0.099
HR, 25% reduction	–	–	131.8 ± 14.0	179.8 ± 24.8	180.3 ± 14.8	Con vs. Dex	< 0.001
						Con vs. Yoh + Dex	< 0.001
						Dex vs. Yoh + Dex	0.096
HR, 50% reduction	–	–	257.1 ± 26.6	326.5 ± 23.7	330.6 ± 28.5	Con vs. Dex	< 0.001
						Con vs. Yoh + Dex	< 0.001
						Dex vs. Yoh + Dex	0.097
HR, 75% reduction	–	–	303.1 ± 20.6	418.1 ± 57.0	424.3 ± 27.2	Con vs. Dex	< 0.001
						Con vs. Yoh + Dex	< 0.001
						Dex vs. Yoh + Dex	0.080
RPP, 25% reduction	–	–	121.9 ± 15.8	165.5 ± 14.3	160.6 ± 13.4	Con vs. Dex	< 0.001
						Con vs. Yoh + Dex	< 0.001
						Dex vs. Yoh + Dex	0.099
RPP, 50% reduction	–	–	223.6 ± 25.5	316.4 ± 23.4	321.3 ± 23.7	Con vs. Dex	< 0.001
						Con vs. Yoh + Dex	< 0.001
						Dex vs. Yoh + Dex	0.093
RPP, 75% reduction	–	–	285.4 ± 29.0	412.6 ± 25.1	409.5 ± 27.3	Con vs. Dex	< 0.001
						Con vs. Yoh + Dex	< 0.001
						Dex vs. Yoh + Dex	0.064

Tabel 1. Data were given as mean ± SD. (n = 8 in each group)
^*P < 0.05 versus Group Con. HR Heart rate, RPP Rate-pressure product, KHB Krebs-Henseleit buffer, Con Control, Dex Dexmedetomidine, Yoh Yohimbine

ISSN: 2050-6511